Eletriptan is filed as Triptan. The sections below restate public label fields stored for this profile.
RELPAX is indicated for the acute treatment of migraine with or without aura in adults.
Eletriptan binds with high affinity to 5-HT 1B , 5-HT 1D and 5-HT 1F receptors, has modest affinity for 5-HT 1A , 5-HT 1E , 5-HT 2B and 5-HT 7 receptors. Migraines are likely due to local cranial vasodilatation and/or to the release of sensory neuropeptides (vasoactive intestinal peptide, substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of RELPAX for the treatment of migraine headache is thought to be due to the agonist effects at the 5-HT 1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.
RELPAX should only be used where a clear diagnosis of migraine has been established.
RELPAX is contraindicated in patients with: • Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal's angina [see Warnings and Precautions (5.1) ]. • Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions (5.2) ]. • History of stroke, transient ischemic attack (TIA), or history or current evidence of hemiplegic or basilar migraine because these patients are at a higher risk of stroke [see Warnings and Precautions (5.4) ]. • Peripheral vascular disease [see Warnings and Precautions (5.5) ]. • Ischemic bowel disease [see Warnings and Precautions (5.5) ]. • Uncontrolled hypertension [see Warnings and Precautions (5.8) ]. • Recent use (i.e., within 24 hours) of another 5-hydroxytryptamine 1 (5-HT 1 ) agonist, ergotamine-containing medication, or ergot-type medication such as dihydroergotamine (DHE) or methysergide [see Drug Interactions (7.1) ] . • Hypersensitivity to RELPAX (angioedema and anaphylaxis seen) [see Warnings and Precautions (5.9) ]. • Recent use (i.e., within at least 72 hours) of the following potent CYP3A4 inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, or nelfinavir [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ].
Asthenia (Common); Nausea (Common); Dizziness (Common); Somnolence (Common)
The following adverse reactions are described elsewhere in other sections of the prescribing information: • Myocardial ischemia and myocardial infarction, and Prinzmetal's angina [see Warnings and Precautions (5.2) ] • Arrhythmias [see Warnings and Precautions (5.3) ] • Chest, throat, neck, and/or jaw pain/tightness/pressure [see Warnings and Precautions (5.4) ] • Cerebrovascular events [see Warnings and Precautions (5.4) ] • Other vasospasm reactions [see Warnings and Precautions (5.5) ] • Medication overuse headache [see Warnings and Precautions (5.6) ] • Serotonin syndrome [see Warnings and Precautions (5.7) ] • Increase in blood pressure [see Warnings and Precautions (5.8) ] • Hypersensitivity reactions [see Contraindications (4) and Warnings and Precautions (5.9) ]
The maximum recommended single dose is 40 mg. In controlled clinical trials, single doses of 20 mg and 40 mg were effective for the acute treatment of migraine in adults. A greater proportion of patients had a response following a 40 mg dose than following a 20 mg dose [see Clinical Studies (14) ] . If the migraine has not resolved by 2 hours after taking RELPAX, or returns after transient improvement, a second dose may be administered at least 2 hours after the first dose. The maximum daily dose should not exceed 80 mg. The safety of treating an average of more than 3 migraine attacks in a 30-day period has not been established.
Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine [DHE] or methysergide) and RELPAX within 24 hours of each other is contraindicated . Concomitant use of other 5-HT 1 agonists within 24 hours of RELPAX treatment is contraindicated [see Contraindications (4) ] .
According to its FDA label, Eletriptan is approved for: RELPAX is indicated for the acute treatment of migraine with or without aura in adults. For medical advice, please talk to your prescriber or pharmacist.
Eletriptan belongs to the Triptan class of medications.
The FDA label lists Eletriptan as: RELPAX should only be used where a clear diagnosis of migraine has been established.; oral route. Available strengths and packaging vary by manufacturer.
Yes. A generic version of Eletriptan is available in the U.S. Ask your pharmacist about substitution.
Our ingest of the FDA label for Eletriptan does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.
The FDA Enforcement Report does not show an active/ongoing recall for Eletriptan in our latest ingest. Recall data can change daily — verify at FDA.gov.
The FDA record lists the approval date for Eletriptan as 2019-01-15.
The FDA label lists Direct_Rx as a labeler/manufacturer of Eletriptan. Multiple firms may market generics of the same molecule.
The FDA label states: "RELPAX Tablets containing 20 mg or 40 mg eletriptan (base) as the hydrobromide salt. RELPAX Tablets are orange, round, convex shaped, film-coated tablets with appropriate debossing. They are supplied in the following str…" Follow the packaging insert for the authoritative guidance.
Loading full data from Know Your Drugs Institute…